Clinical Trial Update: Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of an aromatase inhibitor plus durvalumab in postmenopausal hormone receptor-positive breast cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Aromatase inhibitor (Aromatase inhibitor)
• Durvalumab (durvalumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Breast Cancer, Hormone Receptor Positive Tumor | Phase 2 | Status: TERMINATED | Results posted: 2022-01-11